Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Quarterly Activities and Cash Flow Report Quarter ended 31 December 2019 (ASX:IMU)

Key Highlights: Imugene completes oversubscribed placement of $24.6 million to fund clinical programs on 02- December, 2019 Professor Yuman Fong appointed Chairman of the Oncolytic Virotherapy S...read more

Imugene PD1-Vaxx Immunotherapy Update (ASX:IMU)

Sydney, Australia, 28 January 2020: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announces a clinical development update on its PD1-Vaxx cancer immunotherapy. PD1- Vaxx w...read more

Imugene HER-Vaxx Immunotherapy Patent Granted in United States (ASX:IMU)

Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announced it has received a Notice of Grant from the United States Patent and Trademark Office (USPTO) for Patent Application...read more

Imugene (ASX:IMU) share placement to raise $24.6 million (ASX:IMU)

Key points: - Oversubscribed placement commitments to sophisticated and professional investors to raise $24.6 million - Capital raising fully funds the Company’s clinical programs incl...read more

Imugene Limited (ASX:IMU) - trading halt (ASX:IMU)

The securities of Imugene Limited ('IMU') will be placed in trading halt at the request of IMU, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain...read more

US Defense Grant to Study Imugene CF33 Oncolytic Virotherapy (ASX:IMU)

Sydney, Australia, 23 October 2019: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announced that prominent City of Hope researchers Yanghee Woo, MD, Associate Clinical Profe...read more

Imugene Announce CF33 Oncolytic Virus Clinical Trial Program Update (ASX:IMU)

SYDNEY Australia 21 October 2019: Imugene Limited (ASX: IMU) is pleased to provide an update on the preliminary clinical development plan (CDP) for the proposed exclusive license of the patents coveri...read more

Imugene appoints Professor Yuman Fong, MD, of City of Hope to Chair Oncolytic Virotherapy Scientific Advisory Board (ASX:IMU)

Sydney, Australia, 17 October 2019: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announced the appointment of Professor Yuman Fong, MD, Chair of the Department of Surgery a...read more

Imugene Announce Cancer Vaccine Combinations Presented at ESMO (ASX:IMU)

European Society of Medical Oncology Congress Presentations Show B-Cell Vaccine Combinations Inhibit Cancer Growth in Preclinical Models SYDNEY, Australia, 1 October 2019: Imugene Limited (ASX:IMU)...read more

Imugene Announce Comprehensive Phase Ib HER-Vaxx Results Presented at ESMO (ASX:IMU)

Comprehensive Phase 1b HER-Vaxx Cancer Vaccine Results Presented at the European Society of Medical Oncology (ESMO) Congress SYDNEY, Australia, 1 October 2019: Imugene Limited (ASX:IMU), a clinical...read more

Imugene Enhances Portfolio with Compelling Oncolytic Virus (ASX:IMU)

Imugene Enhances Portfolio with Compelling Oncolytic Virus from City of Hope, a Cancer Centre in Los Angeles, California FDA Investigational New Drug (IND) package Worldwide, exclusive...read more

Imugene Announce New HER-Vaxx Cancer Vaccine trial data presented at ESMO GI (ASX:IMU)

New HER-Vaxx Cancer Vaccine trial data presented at the European Society of Medical Oncology World Congress on Gastrointestinal Cancer SYDNEY, Australia, 8 July 2019: Imugene Limited (ASX:IMU), a c...read more

Imugene announces Updated Phase 1b HER-Vaxx data presented at ASCO (ASX:IMU)

SYDNEY, Australia, 4 June 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced positive data from the ongoing patients in the Phase Ib study of its HER-Vaxx cance...read more

Imugene announces Updated Phase Ib HER-Vaxx data (ASX:IMU)

Imugene announce Global Biotechnology and Venture Capital Executive Joins Imugene Board (ASX:IMU)

SYDNEY Australia 20 May 2019: The Board of Imugene Limited today announced the appointment of leading biotechnology executive and entrepreneur Dr Jens Eckstein as a Non-Executive Director, effective 2...read more

Viewing: 1 - 15 of 51 Previous | Next